Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.

Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF.

Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi: 10.1053/j.gastro.2019.02.038. Epub 2019 Mar 2.

2.

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.

Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF.

Gut. 2018 Apr;67(4):736-745. doi: 10.1136/gutjnl-2016-312577. Epub 2017 Mar 30.

3.

Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF.

Cell Rep. 2016 Oct 25;17(5):1357-1368. doi: 10.1016/j.celrep.2016.09.084.

4.

Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.

Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB.

J Virol. 2016 Jun 24;90(14):6387-6400. doi: 10.1128/JVI.00619-16. Print 2016 Jul 15.

5.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF.

Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.

6.

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.

Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF.

Gut. 2015 Mar;64(3):483-94. doi: 10.1136/gutjnl-2013-306155. Epub 2014 May 21.

7.

Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.

Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13109-13. doi: 10.1073/pnas.1221899110. Epub 2013 Jul 22.

8.

Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.

Fofana I, Zona L, Thumann C, Heydmann L, Durand SC, Lupberger J, Blum HE, Pessaux P, Gondeau C, Reynolds GM, McKeating JA, Grunert F, Thompson J, Zeisel MB, Baumert TF.

J Virol. 2013 Sep;87(18):10405-10. doi: 10.1128/JVI.01691-13. Epub 2013 Jul 17.

9.

A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.

Fofana I, Xiao F, Thumann C, Turek M, Zona L, Tawar RG, Grunert F, Thompson J, Zeisel MB, Baumert TF.

PLoS One. 2013 May 21;8(5):e64221. doi: 10.1371/journal.pone.0064221. Print 2013.

10.

Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.

Lupberger J, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH, Baumert TF.

Hepatology. 2013 Oct;58(4):1225-35. doi: 10.1002/hep.26404. Epub 2013 Sep 5.

PMID:
23519785
11.

HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.

Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, Barnes A, Florentin J, Tawar RG, Xiao F, Turek M, Durand SC, Duong FH, Heim MH, Cosset FL, Hirsch I, Samuel D, Brino L, Zeisel MB, Le Naour F, McKeating JA, Baumert TF.

Cell Host Microbe. 2013 Mar 13;13(3):302-13. doi: 10.1016/j.chom.2013.02.006.

12.

HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells.

Florentin J, Aouar B, Dental C, Thumann C, Firaguay G, Gondois-Rey F, Soumelis V, Baumert TF, Nunès JA, Olive D, Hirsch I, Stranska R.

Blood. 2012 Nov 29;120(23):4544-51. doi: 10.1182/blood-2012-02-413286. Epub 2012 Oct 10.

PMID:
23053572
13.

Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data.

Fredersdorf S, Thumann C, Zimmermann WH, Vetter R, Graf T, Luchner A, Riegger GA, Schunkert H, Eschenhagen T, Weil J.

Cardiovasc Diabetol. 2012 May 23;11:57.

14.

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF.

Nat Med. 2011 May;17(5):589-95. doi: 10.1038/nm.2341. Epub 2011 Apr 24.

15.

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF.

Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4. doi: 10.1053/j.gastro.2010.05.073. Epub 2010 Jun 2.

16.

Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.

Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF.

Hepatology. 2010 Apr;51(4):1144-57. doi: 10.1002/hep.23445.

17.

Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.

Mello IM, Thumann C, Schvoerer E, Soulier E, Pinho JR, Silvestre DA, Queiroz AT, Wolf P, Baumert TF, Keller FS, Pereira CA.

J Viral Hepat. 2009 Oct;16(10):732-7. doi: 10.1111/j.1365-2893.2009.01125.x. Epub 2009 Mar 25.

PMID:
19486468
18.

Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes.

Espuelas S, Thumann C, Heurtault B, Schuber F, Frisch B.

Bioconjug Chem. 2008 Dec;19(12):2385-93. doi: 10.1021/bc8002524.

PMID:
19053315
19.

Hepatitis C virus structural proteins do not prevent human dendritic cell maturation.

Thumann C, Schvoerer E, Abraham JD, Bohbot A, Stoll-Keller F, Aubertin AM, Kieny MP.

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):59-68. doi: 10.1016/j.gcb.2007.12.006. Epub 2008 Mar 4.

20.

Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells.

Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, Hu Z, Liang TJ, Blum HE, Thimme R, Lambotin M, Baumert TF.

J Virol. 2008 Apr;82(7):3466-79. doi: 10.1128/JVI.02478-07. Epub 2008 Jan 23.

21.

Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease.

Schvoerer E, Soulier E, Royer C, Renaudin AC, Thumann C, Fafi-Kremer S, Brignon N, Doridot S, Meyer N, Pinson P, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Zachary P, Baumert T, Stoll-Keller F.

J Infect Dis. 2007 Aug 15;196(4):528-36. Epub 2007 Jun 29.

PMID:
17624837
22.

[Recurrence of hepatitis C virus (HCV) infection after liver transplantation for HCV-related disease: host factors and viral factors implicated in the occurrence and the severity of HCV recurrence].

Schvoerer E, Thumann C, Soulier E, Royer C, Fafi-Kremer S, Brignon N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Jaeck D, Stoll-Keller F.

Pathol Biol (Paris). 2006 Dec;54(10):556-60. Epub 2006 Oct 5. French.

PMID:
17027191
23.

Early decrease in circulating dendritic cells number after liver transplantation could favor hepatitis C virus recurrence.

Schvoerer E, Thumann C, Spohrer S, Soulier E, Royer C, Brignon N, Doridot S, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Jaeck D, Stoll-Keller F.

J Med Virol. 2006 Aug;78(8):1070-5.

PMID:
16789017
24.

Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells.

Espuelas S, Roth A, Thumann C, Frisch B, Schuber F.

Mol Immunol. 2005 Apr;42(6):721-9.

PMID:
15781116
25.

Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells.

Siavoshian S, Abraham JD, Thumann C, Kieny MP, Schuster C.

J Med Virol. 2005 Mar;75(3):402-11.

PMID:
15648076
26.

Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.

Roth A, Espuelas S, Thumann C, Frisch B, Schuber F.

Bioconjug Chem. 2004 May-Jun;15(3):541-53. Erratum in: Bioconjug Chem. 2005 Jul-Aug;16(4):1049.

PMID:
15149182
27.

[Immunomodulating effect of HCV during the development of chronic hepatitis C: toward new therapeutic approaches].

Stoll-Keller F, Schvoerer E, Thumann C, Navas MC, Aubertin AM.

Bull Acad Natl Med. 2003;187(6):1147-60; discussion 1160-1. French.

PMID:
14978874
28.

Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats.

Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J.

Cardiovasc Pathol. 2004 Jan-Feb;13(1):11-9.

PMID:
14761780
29.

Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy.

Schvoerer E, Navas MC, Thumann C, Fuchs A, Meyer N, Habersetzer F, Stoll-Keller F.

J Med Virol. 2003 Aug;70(4):588-93.

PMID:
12794721
30.

Effects of morphine on purified human blood monocytes. Modifications of properties involved in antiviral defences.

Stoll-Keller F, Schmitt C, Thumann C, Schmitt MP, Caussin C, Kirn A.

Int J Immunopharmacol. 1997 Feb;19(2):95-100.

PMID:
9278179

Supplemental Content

Loading ...
Support Center